Department of Korean Medicine Cardiology and Neurology, Graduate School, Kyung Hee University, Seoul.
Department of Korean Internal Medicine, College of Korean Medicine, Gachon University, Gyeonggi-do.
Medicine (Baltimore). 2020 Dec 11;99(50):e23388. doi: 10.1097/MD.0000000000023388.
Despite the rapid advances in medical technology, including endovascular interventions and medications, cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH) is still one of the major threats to the lives of patients with SAH. In East Asian countries, various types of herbal medicines have been used to treat cerebrovascular diseases, including SAH. In this review, we aim to evaluate the efficacy and safety of herbal medicines for the prevention and treatment of CVS after SAH.
Seven databases will be searched for relevant studies from inception to the present date "June 2020". Only randomized controlled trials (RCTs) that assess the effect and safety of herbal medicines for the prevention and treatment of CVS after SAH will be included. The methodological quality will be evaluated using the Cochrane risk of bias assessment tool. After selecting the appropriate studies, a meta-analysis of the RCTs will be performed.
This study will provide a high-quality synthesis of current evidence of herbal medicines for CVS after SAH.
Our systematic review will provide evidence to judge whether herbal medicines are effective interventions for patients with CVS after SAH.
Ethical approval is not required, as this study is based on a review of published research. This review will be published in a peer-reviewed journal and disseminated electronically and in print.
Research registry reviewregistry923.
尽管包括血管内介入治疗和药物治疗在内的医学技术迅速发展,但蛛网膜下腔出血(SAH)后脑血管痉挛(CVS)仍然是 SAH 患者生命的主要威胁之一。在东亚国家,各种草药已被用于治疗包括 SAH 在内的脑血管疾病。在本综述中,我们旨在评估草药治疗 SAH 后 CVS 的预防和治疗的疗效和安全性。
将从建库至 2020 年 6 月检索七个数据库,以评估评估草药治疗 SAH 后 CVS 的预防和治疗效果和安全性的相关研究。仅纳入评估草药治疗 SAH 后 CVS 的预防和治疗效果和安全性的随机对照试验(RCT)。将使用 Cochrane 偏倚风险评估工具评估方法学质量。在选择合适的研究后,将对 RCT 进行荟萃分析。
本研究将对 SAH 后 CVS 的草药治疗的现有证据进行高质量综合。
本系统评价将为判断草药治疗 SAH 后 CVS 是否为有效干预措施提供证据。
本研究基于对已发表研究的回顾,因此不需要伦理批准。本综述将发表在同行评审的期刊上,并以电子和印刷形式传播。
Research registry reviewregistry923。